NCT04451811View on ClinicalTrials.gov

A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

February 24, 2021

Study Completion Date

February 24, 2021

Conditions

Healthy

Interventions

DRUG

OPL-002

Spray dried dispersion and tablet formulation

Trial Locations (1)

BT9 6AD

Celerion, Belfast

Sponsors

Lead Sponsor

Oppilan Pharma Ltd

Collaborators (1)

All Listed Sponsors

collaborator

Celerion

INDUSTRY

lead

Oppilan Pharma Ltd

INDUSTRY